Perpetual Ltd’s Arcutis Biotherapeutics ARQT Stock Holding History

Perpetual Ltd’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.3M	Sell	958,843 -150,814	-14%	-$3.94M	0.39%	71
2026 Q2	$29.1M	Buy	1,109,657 +200,111	+22%	+$4.66M	0.42%	71
2026 Q1	$21.4M	Sell	909,546 -1,084	-0.1%	-$27.7K	0.33%	81
2025 Q4	$26.4M	Sell	910,630 -1,113,976	-55%	-$28.5M	0.38%	65
2025 Q3	$38.2M	Buy	2,024,606 +1,998,086	+7,534%	+$31.5M	0.47%	54
2025 Q2	$372K	Hold	26,520	–	–	﹤0.01%	352
2025 Q1	$415K	Buy	+26,520	New	+$374K	0.01%	350

Other funds holding ARQT

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Perpetual Ltd's ARQT Position: Q3 2026 in Review

Perpetual Ltd reduced its Arcutis Biotherapeutics (ARQT) stake by 14% in Q3 2026, selling an estimated $3.94M and leaving 958,843 shares worth $25.3M. The position accounts for 0.39% of the portfolio, ranked #71.

Perpetual Ltd first reported a position in ARQT in Q1 2025 and has held it in 7 quarters since. The position peaked at $38.2M in Q3 2025. 56 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

Perpetual Ltd held 958,843 shares of Arcutis Biotherapeutics worth $25.3M as of Q3 2026.
Perpetual Ltd sold 150,814 Arcutis Biotherapeutics shares in Q3 2026, an estimated $3.94M.
Arcutis Biotherapeutics made up 0.39% of Perpetual Ltd's portfolio in Q3 2026, its #71 holding.
Perpetual Ltd first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 7 quarters since.
Perpetual Ltd's Arcutis Biotherapeutics position peaked at $38.2M in Q3 2025.
56 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Perpetual Ltd's 13F filing for Q3 2026, filed 13 Oct 2026.